Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms IL2HD
- 19 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 19 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated